Galapagos NV

Galapagos NV (formerly known as Galapagos Genomics) is a European pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel and Zagreb. The CEO is the Dutchman Onno van de Stolpe.

Galapagos NV
Formerly
Galapagos Genomics NV
Naamloze vennootschap
Traded asEuronext: GLPG
NASDAQ: GLPG
ISINBE0003818359 
IndustryPharmaceutical
Founded1999
FounderOnno van de Stolpe 
HeadquartersMechelen, Belgium
Key people
Onno van de Stolpe (CEO), Raj Parekh (Chairman)
Productsfilgotinib; GLPG1205; GLPG0778
Revenue€288.836 million (2018)[1]
€-29.259 million (2018)[1]
Total assets€1,439.496 million (2018)[1]
Total equity€1,214.249 million (2018)[1]
Number of employees
725 (2018)[1]
Websitewww.glpg.com

The company develops drugs against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.[2]

History

Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec.[3] The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.[4]

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

In 2019 Gilead Sciences and Galapagos enterer into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.[5]

Drugs currently under development

See also

References
  1. "Galapagos Annual Report 2018". Galapagos.
  2. Todd Campbel (9 June 2016). "Why Galapagos NV Shares Soared 30.5% in May". The Motley Fool.
  3. "History". Galapagos.
  4. "Galapagos Genomics gaat zelf medicijnen ontwikkelen" [Galapagos Genomics to develop medicines themselves]. Het Nieuwsblad (in Dutch). 16 April 2005.
  5. Gilead and Galapagos Enter Into Transformative Research and Development Collaboration, PM Gilead July 14, 2019, Retrieved 2020-05-09
  6. "Galapagos NV (GLPG) Begins Phase 1 Study with Novel CF Corrector GLPG3221". StreetInsider.com. Retrieved 2017-12-14.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.